Last reviewed · How we verify
Lidocaine post-embolization
At a glance
| Generic name | Lidocaine post-embolization |
|---|---|
| Also known as | Local anesthetic, Amide-type anesthetic, Lidocaine hydrochloride, 00884154 |
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Interventions on the Pelvic Veins in Pelvic Venous Disorders
- Genicular Artery Embolization vs Nerve Ablation Intervention (GENI) for Knee Osteoarthritis (NA)
- The Lowering Weight in Severe Obesity by Embolization of the Gastric Artery Trial (NA)
- Complications of Gonadal Veins Embolization
- Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization (PHASE2)
- Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine post-embolization CI brief — competitive landscape report
- Lidocaine post-embolization updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI